Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10965205 | Vaccine | 2014 | 4 Pages |
Abstract
Plasmid-based vaccines and therapeutics have been making their way into the clinic in the last years. The existence of cost-effective manufacturing processes capable of delivering high amounts of high-quality plasmid DNA (pDNA) is essential to generate enough material for trials and support future commercialization. However, the development of pDNA manufacturing processes is often hampered by difficulties in predicting process scale performance of Escherichia coli cultivation on the basis of results obtained at lab scale. This paper reports on the differences observed in pDNA production when using shake flask and bench-scale bioreactor cultivation of E. coli strains MG1655ÎendAÎrecA and DH5α in complex media with 20 g/L of glucose. MG1655ÎendAÎrecA produced 5-fold more pDNA (9.8 mg/g DCW) in bioreactor than in shake flask (1.9 mg/g DCW) and DH5α produced 4-fold more pDNA (8 mg/g DCW) in bioreactor than in shake flask (2 mg/g DCW). Accumulation of acetate was also significant in shake flasks but not in bioreactors, a fact that was attributed to a lack of control of pH.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Geisa A.L. Gonçalves, Kristala L.J. Prather, Gabriel A. Monteiro, Duarte M.F. Prazeres,